未登录

D

Dzintars Gotham

independent

H指数:20

被引数:1,246

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Understanding adjuvant supply chains for new TB and malaria vaccines

理解新结核病和疟疾疫苗的佐剂供应链

IF3.5

2026-04-220

PRE

Reimbursement models to tackle market failures for antimicrobials: Approaches taken in France, Germany, Sweden, the United Kingdom, and the United States

IF3.4

2021-03-0144

OAAI

Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials

IF3.1

2020-10-0835

PREAI

Price of a hepatitis C cure: Cost of production and current prices for direct-acting antivirals in 50 countries

JOURNAL OF VIRUS ERADICATION

IF2

2020-09-0135

OAAI

How a US-UK trade agreement could affect NHS drug prices

BMJ-BRITISH MEDICAL JOURNAL

IF42.7

2020-06-013

PREAI

Quantifying changes in global health inequality: the Gini and Slope Inequality Indices applied to the Global Burden of Disease data, 1990-2017

BMJ GLOBAL HEALTH

IF6.1

2019-09-2423

OAAI

Production costs and potential prices for biosimilars of human insulin and insulin analogues

BMJ GLOBAL HEALTH

IF6.1

2018-09-2550

OAAI

Estimated costs of production and potential prices for the WHO Essential Medicines List

BMJ GLOBAL HEALTH

IF6.1

2018-01-2965

OAAI

Open letter to the candidates for Director-General of WHO: will you support a patient-centred R&D agreement?

LANCET GLOBAL HEALTH

IF18

2017-02-016

OAAI

Estimated generic prices for novel treatments for drug-resistant tuberculosis

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2017-01-1021

OAAI

Generic treatments for human immunodeficiency virus, hepatitis B virus, hepatitis C virus, TB could be mass-produced for <$90 per patient

JOURNAL OF HEPATOLOGY

IF33

2017-01-010

PREAI

Drug prices threaten the NHS

IF88.5

2016-11-010

OAAI

Global health equity in United Kingdom university research: a landscape of current policies and practices

HEALTH RESEARCH POLICY AND SYSTEMS

IF3.2

2016-10-1010

OAAI

How the MDGs gave up on measuring access to medicines

LANCET GLOBAL HEALTH

IF18

2016-05-0116

OAAI

SIGNIFICANT REDUCTIONS IN COSTS OF GENERIC PRODUCTION OF SOFOSBUVIR AND DACLATASVIR FOR HEPATITIS C TREATMENT IN LOW- AND MIDDLE-INCOME COUNTRIES

JOURNAL OF HEPATOLOGY

IF33

2016-01-010

PREAI

Target prices for mass production of Tyrosine Kinase Inhibitors (TKIs) for global cancer treatment access

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-09-011

PREAI